Healthcare / Medical DevicesKOSDAQ
$2370.00
-130.00 (-5.20%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-1.4B · quality 68.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
36/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
8/100
SEC 0%
Sin guardar todavía.
Market Cap
$26.0B
P/E
10.3x
↓EV/EBITDA
7.4x
↓ROE
13.3%
↑Gross Margin
25.6%
↓Debt/Equity
0.66
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2023 · 1 años de histórico normalizado
Revenue CAGR
+8.9%
FCF CAGR
—
FCF margin
-2.5%
FCF / Net income
-0.40x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $27.78B · net income $1.77B · FCF $-704.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2023 | 2022 |
|---|---|---|---|
| Income Statement | |||
| Revenue | $27.78B | $27.78B | $25.50B |
| Net Income | $1.77B | $1.77B | $-450.9M |
| EBITDA | $3.44B | $3.44B | $1.54B |
| EPS | 229.00 | 229.00 | -75.00 |
| Gross Margin | 25.6% | 25.6% | 24.3% |
| Operating Margin | 8.1% | 8.1% | 6.9% |
| Net Margin | 6.4% | 6.4% | -1.8% |
| Balance Sheet | |||
| Debt/Equity | 0.66 | 0.66 | -5.73 |
| Current Ratio | 1.74 | 1.74 | — |
| Cash Flow | |||
| Free Cash Flow | $-704.8M | $-704.8M | $-2.03B |
| Returns | |||
| ROE | 13.3% | 13.3% | 28.0% |
| Valuation | |||
| P/E | 10.35 | 10.35 | — |
| EV/EBITDA | 7.39 | 7.39 | — |
| P/B | 1.38 | 1.38 | — |
| Growth & Yield | |||
| Revenue Growth | 8.9% | 8.9% | — |
| EPS Growth | 405.3% | 405.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-2.8%
EPS terminal req.
$210.30
Spread vs growth
408.1%
5Y implied EPS CAGR
2.1%
EPS terminal req.
$254.46
Spread vs growth
403.2%
10Y implied EPS CAGR
6.0%
EPS terminal req.
$409.81
Spread vs growth
399.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-29.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-75.00 → 229.00
Residual
-29.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.